Spyridon Gkalpakiotis

Prague, PR, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 82 publications

Efficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry.

Efficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry.

Journal: The Journal of dermatological treatment

Published: July 10, 2026

Prevalence of Regulatory Safety Risk Factors Among Adolescents and Adults With Atopic Dermatitis Receiving Advanced Systemic Therapies: An International Real-World Study.

Prevalence of Regulatory Safety Risk Factors Among Adolescents and Adults With Atopic Dermatitis Receiving Advanced Systemic Therapies: An International Real-World Study.

Journal: International journal of dermatology

Published: July 02, 2026

A Delphi Consensus on Tildrakizumab Dosing and Titration in Moderate-to-Severe Plaque Psoriasis.

A Delphi Consensus on Tildrakizumab Dosing and Titration in Moderate-to-Severe Plaque Psoriasis.

Journal: Acta dermato-venereologica

Published: April 07, 2026

Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.

Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.

Journal: Lancet (London, England)

Published: March 06, 2026

Severe generalized pustular psoriasis complicated with staphylococcal toxic shock syndrome treated with spesolimab and antibiotics.

Severe generalized pustular psoriasis complicated with staphylococcal toxic shock syndrome treated with spesolimab and antibiotics.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Published: January 04, 2026

WHO-5 Well-Being Index Reveal the Burden of Hidradenitis Suppurativa.

WHO-5 Well-Being Index Reveal the Burden of Hidradenitis Suppurativa.

Journal: International journal of dermatology

Published: December 08, 2025

Clinical Trial Eligibility in Atopic Dermatitis: Data from a Large Real-World International Cohort.

Clinical Trial Eligibility in Atopic Dermatitis: Data from a Large Real-World International Cohort.

Journal: Dermatology and therapy

Published: November 14, 2025

Efficacy and Safety Evaluation of Different Lebrikizumab Dosages in Atopic Dermatitis Patients Over 16 to 24 Weeks: A BIOREP Registry Analysis.

Efficacy and Safety Evaluation of Different Lebrikizumab Dosages in Atopic Dermatitis Patients Over 16 to 24 Weeks: A BIOREP Registry Analysis.

Journal: International journal of dermatology

Published: October 17, 2025

Atopic Dermatitis Successfully Treated with Lebrikizumab in Real-World Clinical Practice in Czech Republic: A Case Series.

Atopic Dermatitis Successfully Treated with Lebrikizumab in Real-World Clinical Practice in Czech Republic: A Case Series.

Journal: Dermatology and therapy

Published: September 19, 2025

European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol.

European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol.

Journal: BMJ open

Published: July 11, 2025

Super-Response to Guselkumab Treatment in Patients With Moderate-to-Severe Psoriasis: Real-World Data With Up to Five Years of Follow-Up in The Czech Republic.

Super-Response to Guselkumab Treatment in Patients With Moderate-to-Severe Psoriasis: Real-World Data With Up to Five Years of Follow-Up in The Czech Republic.

Journal: International journal of dermatology

Published: May 21, 2025

Efficacy and safety of lebrikizumab in atopic dermatitis over 24 weeks: An analysis from the BIOREP registry.

Efficacy and safety of lebrikizumab in atopic dermatitis over 24 weeks: An analysis from the BIOREP registry.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: May 12, 2025

Showing 1-12 of 82

Last Updated: 09/26/2026